Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Society for Immunotherapy of Cancer Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design | ||
By: PR Newswire Association LLC. - 23 Apr 2024 | Back to overview list |
|
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease" in the Journal for ImmunoTherapy of Cancer. MILWAUKEE, April 23, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease" in the Journal for ImmunoTherapy of Cancer. "With the recommendations provided in the manuscript, researchers can optimize clinical trial design and the delivery of intratumoral immunotherapies." - Jason Luke, MD, FACP, chair of the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to date, in part due to the complex nature of these trials not fully adapted to assess local therapies. The aim for this manuscript is to provide guidance on how to design trials with the greatest likelihood of demonstrating the benefits of intratumoral immunotherapy across all stages of pathogenesis and ultimately bring more effective options to patients. "Intratumoral delivery has great potential to deliver precise and potent immunotherapies to particular disease sites and tumor microenvironments. Despite this, clinical development of intratumoral immunotherapies in metastatic cancer has been fraught with negative clinical trials and many open questions." said Jason Luke, MD, FACP, chair of the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group. "With the recommendations provided in the manuscript, researchers can optimize clinical trial design and the delivery of intratumoral immunotherapies." Expert Panel Recommendations for Trial Design
Supplemental Guidance on Localized Therapy Administration While intratumoral immunotherapy is a potentially effective monotherapy when used in the optimal disease settings, it may also increase the effectiveness of systemic treatments without the cost of added toxicity. With more effective and standardized trial designs, the potential of intratumoral immunotherapy can be realized and lead to regulatory approvals that will extend the benefit of these local treatments to the patients who need them the most. About SITC About JITC Media Contact Thomas Martin, Society for Immunotherapy of Cancer, 414.271.2456, tmartin@sitcancer.org, www.sitcancer.org View original content to download multimedia:https://www.prweb.com/releases/society-for-immunotherapy-of-cancer-publishes-recommendations-on-optimal-intratumoral-immunotherapy-clinical-trial-iict-design-302124798.html SOURCE Society for Immunotherapy of Cancer |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |